Xanomeline/trospium
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia; Psychosis
Conditions
Schizophrenia; Psychosis, Cognitive Impairment
Trial Timeline
Jan 14, 2026 → Jul 1, 2028
NCT ID
NCT07084831About Xanomeline/trospium
Xanomeline/trospium is a phase 3 stage product being developed by Bristol Myers Squibb for Schizophrenia; Psychosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07084831. Target conditions include Schizophrenia; Psychosis, Cognitive Impairment.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia; Psychosis were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07084831 | Phase 3 | Recruiting |
| NCT06923891 | Approved | Recruiting |
Competing Products
20 competing products in Schizophrenia; Psychosis